Fractyl Health FY2025 EPS Estimate Boosted by HC Wainwright

Fractyl Health, Inc. (NASDAQ:GUTS) – Equities research analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Fractyl Health in a report issued on Thursday, November 13th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($1.15) per share for the year, up from their prior forecast of ($1.72). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health’s Q4 2025 earnings at ($0.14) EPS, FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.04) EPS and FY2029 earnings at $0.31 EPS.

Several other research analysts also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Fractyl Health in a research report on Wednesday, October 8th. LADENBURG THALM/SH SH began coverage on Fractyl Health in a report on Thursday, August 28th. They set a “buy” rating and a $3.60 target price for the company. Finally, Canaccord Genuity Group decreased their target price on Fractyl Health from $12.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $6.90.

Fractyl Health Stock Performance

GUTS opened at $1.40 on Monday. The firm’s fifty day simple moving average is $1.24 and its two-hundred day simple moving average is $1.46. Fractyl Health has a 52-week low of $0.83 and a 52-week high of $3.03. The company has a market cap of $70.41 million, a price-to-earnings ratio of -0.61 and a beta of 2.20. The company has a quick ratio of 4.27, a current ratio of 4.27 and a debt-to-equity ratio of 4.61.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nantahala Capital Management LLC acquired a new stake in shares of Fractyl Health in the third quarter valued at approximately $19,298,000. Alyeska Investment Group L.P. purchased a new stake in Fractyl Health in the 3rd quarter valued at $8,981,000. Woodline Partners LP grew its holdings in Fractyl Health by 821.1% in the 3rd quarter. Woodline Partners LP now owns 5,506,534 shares of the company’s stock valued at $8,755,000 after buying an additional 4,908,693 shares in the last quarter. Rosalind Advisors Inc. acquired a new stake in shares of Fractyl Health in the 3rd quarter worth $7,950,000. Finally, General Catalyst Group Management LLC purchased a new position in shares of Fractyl Health during the 2nd quarter worth $7,912,000.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.